

4-7-03



PATENT
Docket No. 1400-002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

WILLIAM J. ROBERTS

Entitled: "BIOAVAILABLE PRODRUGS OF
ANDROGENIC STEROIDS AND RELATED
METHOD"

Serial No.: 09/872,705

Filed: June 1, 2001

Group Art Unit: 1616

Examiner: Qazi, Sabiha Naim

RECEIVED
APR 09 2003
TECH CENTER 1600/2900

Assistant Commissioner for Patents
U.S. Patent and Trademark Office
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Applicant hereby submits this Information Disclosure Statement under 37 C.F.R. §§ 1.56 and 1.97(c) to bring to the attention of the Examiner the documents listed on the attached Form PTO/SB/08A. It is being filed after the occurrence of events identified in § 1.97(b), but upon information and belief before the mailing date of either a final office action or a notice of allowance. Copies of the listed documents are attached.

Applicant also brings to the attention of the Examiner the following co-pending applications, a copy of each of which is attached:

1. Serial No. 10/053,345 to Roberts (Attorney Docket No. 1400-003);
2. Serial No. 10/053,505 to Roberts (Attorney Docket No. 1400-004); and

100.00 DP
04/08/2003 09872705
10081:CF 10

3. Serial No. 10/265,218 to Roberts (Attorney Docket No. 1400-063).

Please initial this Information Disclosure Statement next to each of the above-listed co-pending applications, and return a copy of the initialed IDS to Applicant with the next written communication.

The fee set forth in 37 C.F.R. § 1.17(p) required by 37 C.F.R. § 1.97(c) in lieu of certification is filed herewith. Should that fee be deficient, please charge the deficiency to our Deposit Account 501324 under Order No. 1400-002.

This submission does not represent that a search has been made or that no better art exists. Nor does it constitute an admission that any or all of the listed documents are material or constitute "prior art." Applicant reserves the right to challenge the characterization of any of these documents or information as "prior art." Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Consideration of the foregoing and enclosures plus return of a copy of the herewith Form PTO/SB/08A with the Examiner's initials in the left column per MPEP 609 along with an early action on the merits of this application are earnestly requested.

Dated: April 3, 2003

Respectfully submitted,

A handwritten signature in cursive script, appearing to read "Sarah L. Malcolm".

Sarah L. Malcolm
Reg. No. 53,259

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	09/872,705
Filing Date	June 1, 2001
First Named Inventor	William J. Roberts
Group Art Unit	1616
Examiner Name	Qazi, Sabiha Naim
Attorney Docket Number	1400-002

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US-2,843,608	07-15-1958	Colton	
		US- 3,056,727	10-02-1962	Allais et al.	
		US- 3,314,856	04-18-1967	Allais et al.	
		US- 3,433,813	03-18-1969	Boswell	
		US- 3,435,030	03-25-1969	Klimstra	
		US- 3,481,957	12-02-1969	Cross et al.	
		US- 3,523,126	08-04-1970	Boswell	
		US- 4,087,524	05-02-1978	Grunwell et al.	
		US- 4,239,681	12-16-1980	Grunwell et al.	
		US- 5,053,403	10-01-1991	Orentreich et al.	
		US- 5,387,583	02-07-1995	Loria	
		US- 5,391,776	02-21-1995	Ueno et al.	
		US- 5,578,588	11-26-1996	Mattern et al.	
		US- 5,880,117	03-09-1999	Arnold	
		US- 6,011,027	01-04-2000	Arnold	
		US- 6,017,964	01-25-2000	MacLean et al.	
		US- 6,117,429	09-12-2000	Bucci	
		US- 2001/0041698 A1	11-15-2001	Arnold	
		US- 2001/0056087 A1	12-27-2001	Arnold	
		US- 2002/0183532 A1	12-05-2002	Roberts	

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner
Signature


Date
Considered

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**



PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	09/872,705		
		Filing Date	June 1, 2001		
		First Named Inventor	William J. Roberts		
		Group Art Unit	1616		
		Examiner Name	Qazi, Sabiha Naim		
Sheet	2	of	2	Attorney Docket Number	1400-002

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BLAQUIER et al., "In Vitro Metabolism of Androgens in Whole Human Blood", Acta Endocrinologica, May-August 1967, 697-704, Vol. 55, Periodica, Copenhagen.	
		EARNEST et al., "In Vivo 4-androstene-3,17-dione and 4-androstene-3 β ,17 β -diol Supplementation in Young Men", European Journal of Applied Physiology, February 2000, 229-232, Vol. 81, No. 3, Springer, New York.	
		FRANKE et al., "Hormonal Doping and Androgenization of Athletes: A Secret Program of the German Democratic Republic Government", Clinical Chemistry, Nov. 7, 1997, 1262-1279, Vol. 43, No. 7, American Association for Clinical Chemistry, United States of America.	
		INABA et al., "Conversion of 4-Androstenediol and 5-Androstenediol to Testosterone, and Conversion of Dehydroepiandrosterone to 4-Androstenediol by Rat Testis In Vitro", Endocrinol. June 1966, 160-172, Vol. 13, No. 2, Japan.	
		URALETS et al., "Over-the-Counter Anabolic Steroids 4-Androsten-3, 17-dione; 4-Androsten-3 β ,17 β -diol; and 19-nor-4-Androsten-3, 17-dione: Excretion Studies in Men", Journal of Analytical Toxicology, September 1999, 357-366, Vol. 23, : Preston Publications, Niles, Illinois.	
		YAMAJI et al., "Androstenediol in Canine Spermatic Vein Blood and Its Significance in Testosterone Biosynthesis in Vivo", Endocrinology, 1968, 992-998, Vol. 83, J. B. Lippincott, Philadelphia.	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.